Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bicalutamide

FDA-approved product (tablet, oral), marketed as Bicalutamide, Casodex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Bicalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bicalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bicalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

    NCT00223145 · start 2000-12

    Registered record
    Registry ID
    NCT00223145
    Conditions
    Prostate Cancer
    Interventions
    Radiotherapy 70 Gy; Radiotherapy 76 Gy; Androgen blockade
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2000-12
    Completion
    2027-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiotherapy 70 Gy; Radiotherapy 76 Gy; Androgen blockade
    PhasePhase 3
    Registry statusActive not recruiting

  • Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

    NCT00536653 · start 1999-10

    Registered record
    Registry ID
    NCT00536653
    Conditions
    Osteoporosis
    Interventions
    Bicalutamide and Calcium/ Vitamin D supplementation; LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation; LHRH agonists (Goserelin acetate)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-10
    Completion
    2007-01
    Enrolment
    618

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBicalutamide and Calcium/ Vitamin D supplementation; LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation; LHRH agonists (Goserelin acetate)
    PhaseNot applicable
    Registry statusCompleted

  • Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

    NCT00841113 · start 1999-01

    Registered record
    Registry ID
    NCT00841113
    Conditions
    Prostate Cancer
    Interventions
    Abarelix; Goserelin plus Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01
    Completion
    2003-02
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbarelix; Goserelin plus Bicalutamide
    PhasePhase 3
    Registry statusCompleted

  • Hormone Therapy in Treating Patients With Advanced Prostate Cancer

    NCT00003026 · start 1997-04

    Registered record
    Registry ID
    NCT00003026
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; triptorelin; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-04
    Completion
    Not recorded
    Enrolment
    966

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; triptorelin; radiation therapy
    PhasePhase 3
    Registry statusCompleted

  • (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

    NCT00673205 · start 1995-09

    Registered record
    Registry ID
    NCT00673205
    Conditions
    Non-Metastatic Prostate Cancer
    Interventions
    Bicalutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-09
    Completion
    2008-08
    Enrolment
    3,588

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Metastatic Prostate Cancer
    InterventionBicalutamide; Placebo
    PhasePhase 3
    Registry statusCompleted